Shire PLC (LON:SHP) has been reiterated to Overweight in a report by JP Morgan Cazenove today.
- Updated: September 25, 2016
JP Morgan Cazenove has reiterated Shire PLC (LON:SHP) to Overweight in a report released on 9/26/2016.
Boasting a price of 5,215.00GBX, Shire PLC (LON:SHP) traded -0.48% lower on the day. With the last close up 16.12% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Shire PLC has recorded a 50-day average of 4,986.92GBX and a two hundred day average of 4,463.41GBX. Volume of trade was down over the average, with 32,846 shares of SHP changing hands under the typical 2,143,900
With a total market value of 0 GBX, Shire PLC has price-earnings ratio of 32.31 with a one year low of 2,707.19GBX and a one year high of 5,377.00GBX .
A total of 18 brokerages have issued a ratings update on Shire PLC. Six brokerages rating the company a strong buy, sixteen brokerages rating the company a buy, zero firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of 73.73GBX.
General Information About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.